The efficacy and safety of intravitreal ranibizumab in diabetic macular oedema (DMO) has been evaluated in two parallel, methodologically identical, phase III, studies (RISE and RIDE).
The studies involved adults with vision loss from DMO (best-corrected visual acuity [BCVA], 20/40 to 20/320 Snellen equivalent) and central subfield thickness ? 275 microm on time-domain optical coherence tomography (OCT). They were randomised to receive monthly intravitreal ranibizumab (0.5 or 0.3 mg) or sham injections. Macular laser was available per-protocol-specified criteria. The main outcome measure was the proportion (Read more...)